Imperial College London Featured PhD Programmes
Engineering and Physical Sciences Research Council Featured PhD Programmes
University of Reading Featured PhD Programmes
"drug" AND "development"×
10 miles

drug development PhD Projects, Programs & Scholarships

We have 230 drug development PhD Projects, Programs & Scholarships

  • "drug" AND "development" ×
  • clear all
Order by 
Showing 1 to 15 of 230
  Pharmacometrics modelling-based dose-finding and synthetic control arms established using longitudinal analyses to improve efficiency in oncology clinical drug development.
  Prof M Chappell
Application Deadline: 30 June 2020

Funding Type

PhD Type

Advancements in the field of oncology are rapidly changing the life expectancy of patients across many cancers.
  EPSRC Centre for Doctoral Training in Sustainable Approaches to Biomedical Science: Responsible and Reproducible Research - SABS

Funding Type

PhD Type

Good degree in the Physical or Life Sciences? Interested in biological or medical research? We offer fully-funded PhD places across the Oxford Doctoral Training Centre programmes.
  Development of pulmonary dosage forms for improved antibacterial activity
  Dr H Al-Obaidi
Applications accepted all year round

Funding Type

PhD Type

"Conventional formulations for drug delivery to the lungs are limited to less than a few milligrams as a fine particle fraction.
  Combined use of in-vitro and in-silico models for drug discovery
  Dr I Khadra, Prof G Halbert
Application Deadline: 1 June 2020

Funding Type

PhD Type

This project is one of 16 four year PhD Studentships funded by Medical Research Scotland (https://www.medicalresearchscotland.org.uk) to be delivered jointly by the named University and External Partner Organisation (EPO).
  How can public support be fostered for controversial, but evidence-based, drug policies that will improve outcomes for stigmatised and marginalised groups?
  Dr H R Sumnall, Dr A Atkinson, Dr S Gage, Dr I Hamilton
Applications accepted all year round

Funding Type

PhD Type

The UK is currently facing some of the highest levels of deaths related to controlled drug use on record. People who use drugs (PWUD) also face other health and social harms related to their drug use, and because of the ways in which society chooses to respond to their drug use.
  Nanotechnologies for cancer: developing new polymer-drug conjugates for the treatment of a range of cancers
  Dr F Greco, Prof H Osborn
Applications accepted all year round

Funding Type

PhD Type

Polymer anticancer-drug conjugates are drug delivery systems in which a low molecular weight anticancer agent is covalently conjugated to a water-soluble polymeric carrier.
  Investigating the impact of particle manufacturing process on nanomedicine biological fate
  Dr Z Rattray, Prof Y Perrie
Application Deadline: 30 June 2020

Funding Type

PhD Type

A new drug candidate faces multiple challenges during its development, and in oncology drug development, a key challenge is achieving the balance between efficacy and off-target toxicity.
  Exploring the transcriptomic and chromatin landscapes of fibroblast-like synoviocytes in rheumatoid arthritis
  Dr S Eyre, Mr P Martin, Dr AM Morris
Applications accepted all year round

Funding Type

PhD Type

Genetic studies in rheumatoid arthritis (RA) have been successful in identifying regions of the genome which contribute to disease risk, but it is often unclear which genes they effect.
  Discovery of chemical and biological tools to probe hypoxic solid tumours
  Research Group: Institute of Cancer Therapeutics
  Dr K Pors, Dr J Elies Gomez
Applications accepted all year round

Funding Type

PhD Type

A major challenge in cancer therapy is to develop therapeutic agents that selectively target tumour cells. One avenue towards the development of more selective cancer therapies is to exploit the unique physiological properties of solid tumours using prodrug approaches.
  PhD in Chemical Biology -- Neuropeptide Research -- University of Vienna
  Prof M Muttenthaler
Applications accepted all year round

Funding Type

PhD Type

Neuropeptides are key mediators in many biological functions and understanding their interaction with target proteins is fundamental to unravel the underlying mechanism of diseases.
  Academic Endocrine Unit: investigating the molecular basis of endocrine and metabolic disorders that principally affect calcium and phosphate homeostasis.
  Prof R Thakker, Dr K Lines, Dr M Stevenson, Dr K Kooblall
Application Deadline: 24 July 2020

Funding Type

PhD Type

Other Potential Supervisors. Dr Asha Bayliss. The Academic Endocrine Unit investigates the molecular basis of endocrine and metabolic disorders that principally affect calcium and phosphate homeostasis.
  Adjuvant therapies for mupirocin-resistant bacteria
  Dr B Bonev, Dr A Cockayne
Applications accepted all year round

Funding Type

PhD Type

Multi-drug resistant Staphylococcus aureus has been able to adapt constantly to therapeutic use of antibiotics and remains an important source of clinical complications, morbidity and mortality.
  Protein complexes required for bacterial cell wall biosynthesis and division
  Prof D Roper, Dr A Crow, Dr M Jenner, Prof T R Dafforn
Application Deadline: 7 June 2020

Funding Type

PhD Type

Antimicrobial Resistance (AMR) is now widely understood to be a global healthcare emergency, exacerbated by many socio-economic factors.
  Development of novel antibody-nanoparticles conjugates (part of the ETN Targeted Anti-Cancer Therapies “TACT”)
  Research Group: Centre for Cancer Research and Cell Biology
  Prof C Scott, Dr K McCloskey
Application Deadline: 1 June 2020

Funding Type

PhD Type

Kadcyla® is an ADC that has been given FDA approval in early 2013 for the treatment of metastatic breast cancer. However, issues with the toxicity of the highly potent payload (e.g.
  Modification of marketed dosage forms for administration to children
  Dr F O'Brien, Dr M Peak
Applications accepted all year round

Funding Type

PhD Type

Can guidance be provided to allow pharmaceutical companies to develop approvable strategies for alternative methods of administration of medicines to children when the marketed dosage form does not provide the required dose and/or is not acceptable to the child or carers?.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2020
All rights reserved.